Recommendations for the Management of Uveitis Associated With Juvenile Idiopathic Arthritis: The Czech and Slovak adaptation of SHARE Initiative

Czech version

Authors: H. Malcová ¹; T. Dallos ²; K. Bouchalova ³; I. Brejchová ⁴; M. Brichová ⁵; B. Bušányová ⁶; J. Fabianová ⁷; J. Fráňová ⁸; A. Furdová ⁹; K. Jarošová ¹⁰; K. Kobrová ¹¹; B. Kostolná ⁶; E. Košková ¹²; M. Lokaj ¹³; M. Macků ⁸; J. Melocíková ¹⁴; M. Michaličková ⁵; L. Minxová ¹⁵; D. Moravčíková ¹⁴; D. Němcová ¹⁶; T. Pískovský ¹⁷; E. Říhová ⁵; M. Schüller ⁷; E. Skalická ¹⁸; P. Svozílková ⁵; D. Tomčíková ⁶; V. Vargová ¹⁹; E. Vrtíková ¹²; P. Doležalová ¹⁶; prof. MUDr. Jarmila Heissigerová, Ph.D., MBA ⁵
Authors‘ workplace: Oddělení revmatologie dětí a dospělých, Fakultní nemocnice v Motole, Praha, ČR ¹; Detská klinika LF UK v Bratislave a NÚDCH, Bratislava, SR ²; Dětská klinika, LF UP a FN Olomouc, ČR ³; Nemocnice České Budějovice, ČR ⁴; Oční klinika VFN a 1. LF UK, Praha, ČR ⁵; Klinika detskej oftalmológie LF UK a NÚDCH, Bratislava, SR ⁶; NUTPCHaHCH Vyšné Hágy I, Vysoké Tatry, SR ⁷; Pediatrická klinika LF MU a FN Brno, ČR ⁸; Očná klinika LFUK v Bratislave a UNB, Bratislava, SR ⁹; Revmatologický ústav, Praha, ČR ¹⁰; Dětská klinika Masarykovy nemocnice, Ústí nad Labem, ČR ¹¹; Národný ústav reumatických chorôb, Piešťany, SR ¹²; Dětská oční klinika LF MU a FN Brno, ČR ¹³; II. detská klinika SZU DFNsP, Banská Bystrica, SR ¹⁴; Dětská klinika LF UK a FN Hradec Králové, ČR ¹⁵; Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze, ČR ¹⁶; Klinika dětského lékařství, Fakultní nemocnice Ostrava, ČR ¹⁷; Dětská klinika LF UK a FN Plzeň, ČR ¹⁸; Klinika detí a dorastu, LF UPJŠ Košice, SR ¹⁹
Published in: Čes. a slov. Oftal., 76, 2020, No. 4, p. 182-196
Category:
doi: https://doi.org/10.31348/2020/7

Overview

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and uveitis is its most important extra-articular manifestation. Evidence-based recommendations are available only to a limited extent and therefore JIA associated uveitis management is mostly based on physicians’ experience. Consequently, treatment practices differ widely, both nationally and internationally. Therefore, an effort to optimize and publish recommendations for the care of children and young adults with rheumatic diseases was launched in 2012 as part of the international project SHARE (Single Hub and Access Point for Pediatric Rheumatology in Europe) to facilitate clinical practice for paediatricians and (paediatric) rheumatologists.

The aim of this work was to translate published international SHARE recommendations for the diagnosis and treatment of JIA associated uveitis and to adapt them for use in the Czech and Slovak Republics.

International recommendations were developed according to the standard methodology of the European League against Rheumatism (EULAR) by a group of nine experienced paediatric rheumatologists and three experts in ophthalmology. It was based on a systematic literature review and evaluated in the form of an online survey and subsequently discussed using a nominal group technique. Recommendations were accepted if  > 80% agreement was reached (including all three ophthalmologists).

A total of 22 SHARE recommendations were accepted: 3 on diagnosis, 5 on disease activity assessment, 12 on treatment and 2 on future recommendations. Translation of the original text was updated and modified with data specific to the czech and slovak health care systems and supplemented with a proposal for a protocol of ophthalmological dispensarization of paediatric JIA patients and a treatment algorithm for JIA associated uveitis.

Conclusion: The aim of the SHARE initiative is to improve and standardize care for paediatric patients with rheumatic diseases across Europe. Therefore, recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated based on the evidence and agreement of leading European experts in this field.

Keywords:

recommendation – juvenile idiopathic arthritis (JIA) – Uveitis

Sources

1. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329–340.

2. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74:8–13.

3. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J. 2010;182: E839–842.

4. Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121–1133.

5. Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35:777–785.

6. Zierhut M, Heiligenhaus A, deBoer J, Cunningham ET, Tugal-Tutkun I. Controversies in juvenile idiopathic arthritis-associated uveitis. Ocul Immunol Inflamm. 2013;21:167–179.

7. Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatric Rheumatology. 2016;14(1):27.

8. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11:338–348.

9. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–1311.

10. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312–1324.

11. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004;63:1172–1176.

12. Van de Ven AH, Delbecq AL. The nominal group as a research instrument for exploratory health studies. Am J Public Health. 1972;62:337–342.

13. Uchiyama RC, Osborn TG, Moore TL. Antibodies to iris and retina detected in sera from patients with juvenile rheumatoid arthritis with iridocyclitis by indirect immunofluorescence studies on human eye tissue. J Rheumatol. 1989;16:1074–1078.

14. Giannini EH, Malagon CN, Van Kerckhove C, et al. Longitudinal analysis of HLA associated risks for iridocyclitis in juvenile rheumatoid arthritis. J Rheumatol. 1991;18:1394–1397.

15. Malagon C, Van Kerckhove C, Giannini EH, et al. The iridocyclitis of early onset pauciarticular juvenile rheumatoid arthritis: outcome in immunogenetically characterized patients. J Rheumatol.1992;19:160–163.

16. Murray KJ, Szer W, Grom AA, et al. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. J Rheumatol. 1997;24:560–567.

17. Berk AT, Koçak N, Ünsal E. Uveitis in juvenile arthritis. Ocul Immunol Inflamm. 2001;9:243–251.

18. Zulian F, Martini G, Falcini F, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol. 2002;29:2446–2453.

19. Chia A, Lee V, Graham EM, Edelsten C. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol. 2003;135:757–762.

20. Chen CS, Roberton D, Hammerton ME. Juvenile arthritis-associated uveitis: visual outcomes and prognosis. Can J Ophthalmol. 2004;39:614–620.

21. Nordal EB, Songstad NT, Berntson L, Moen T, Straume B, Rygg M. Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol. 2009;36:1737–1743.

22. Kalinina Ayuso V, Ten Cate HA, van der Does P, Rothova A, de Boer JH. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2010;149:994–999.

23. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1824–1828.

24. Angeles-Han ST, Pelajo CF, Vogler LB, et al. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol. 2013;40:2088–2096.

25. Cole TS, Frankovich J, Iyer S, Lependu P, Bauer-Mehren A, Shah NH. Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: a new model for EHR-based research. Pediatr Rheumatol Online J. 2013;11:45.

26. Calandra S, Gallo MC, Consolaro A, et al. Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. J Rheumatol. 2014;41:1416–1425.

27. Pelegrín L, Casaroli-Marano R, Antón J, et al. Predictive value of selected biomarkers, polymorphisms, and clinical features for oligoarticular juvenile idiopathic arthritisassociated uveitis. Ocul Immunol Inflamm. 2014;22:208–212.

28. Egeskjold EM, Johansen A, Permin H, Hoyeraal HM, Sorensen T. The significance of antinuclear antibodies in juvenile rheumatoid arthritis associated with chronic bilateral iridocyclitis. Acta Paediatr Scand. 1982;71:615–620.

29. Cabral DA, Petty RE, Malleson PN, Ensworth S, McCormick AQ, Shroeder ML. Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol. 1994;21:2370–2375.

30. Haas JP, Truckenbrodt H, Paul C, Hoza J, Scholz S, Albert ED. Subtypes of HLA-DRB1*03, *08, *11, *12, *13 and *14 in early onset pauciarticular juvenile chronic arthritis (EOPA) with and without iridocyclitis. Clin Exp Rheumatol. 1994;12(Suppl 10):7–14.

31. Kotaniemi K, Kotaniemi A, Savolainen A. Uveitis as a marker of active arthritis in 372 patients with juvenile idiopathic seronegative oligoarthritis or polyarthritis. Clin Exp Rheumatol. 2002;20:109–112.

32. Zeggini E, Packham J, Donn R, et al. Association of HLA-DRB1*13 with susceptibility to uveitis in juvenile idiopathic arthritis in two independent data sets. Rheumatology. 2006;45:972–974.

33. Bloom JN, Ni M, Moore TL, Osborn TG, Hageman GS. Serum antiocular antibodies in patients with juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus. 1993;30:243–248.

34. Campanilho-Marques R, Bogas M, Ramos F, Santos MJ, Fonseca JE. Prognostic value of antinuclear antibodies in juvenile idiopathic arthritis and anterior uveitis. Results from a systematic literature review. Acta Reumatol Port. 2014;39:116–122.

35. de Boer J, Steijaert A, van den Bor R, Stellato R, Ossewaarde-van Norel J. Development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2015;23:67–73.

36. Ducos de Lahitte G, Terrada C, Tran TH, et al. Maculopathy in uveitis of juvenile idiopathic arthritis: an optical coherence tomography study. Br J Ophthalmol. 2008;92:64–69.

37. Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:51–56.

38. Glass D, Litvin D, Wallace K, et al. Early-onset pauciarticular juvenile rheumatoid arthritis associated with human leukocyte antigen-DRw5, iritis, and antinuclear antibody. J Clin Invest. 1980;66:426–429.

39. Grassi A, Corona F, Casellato A, Carnelli V, Bardare M. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease. J Rheumatol. 2007;34:1139–1145.

40. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K, German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology. 2007;46:1015–1019.

41. Ingegnoli F, Del Papa N, Comina DP, et al. Autoantibodies to chromatin: prevalence and clinical significance in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:499–501.

42. Kanski JJ. Screening for uveitis in juvenile chronic arthritis. Br J Ophthalmol. 1989;73:225–228.

43. Kodsi SR, Rubin SE, Milojevic D, Ilowite N, Gottlieb B. Time of onset of uveitis in children with juvenile rheumatoid arthritis. J Aapos. 2002;6:373–376.

44. Kotaniemi K, Sihto-Kauppi K. Occurrence and management of ocular hypertension and secondary glaucoma in juvenile idiopathic arthritis-associated uveitis: An observational series of 104 patients. Clin Ophthalmol. 2007;1:455–459.

45. Marvillet I, Terrada C, Quartier P, Quoc EB, Bodaghi B, Prieur AM. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine. 2009;76:383–388.

46. Mathur G, Biswas J. Systemic associations of anterior uveitis in a tertiary care ophthalmic centre in south India. Int Ophthalmol. 2012;32:417–421.

47. McGill NW, Gow PJ. Juvenile rheumatoid arthritis in Auckland: a long term follow-up study with particular reference to uveitis. Aust N Z J Med. 1987;17:305–308.

48. Melin-Aldana H, Giannini EH, Taylor J, et al. Human leukocyte antigen-DRB1*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. J Pediatr. 1992;121:56–60.

49. Merayo-Lloves J, Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS. Secondary glaucoma in patients with uveitis. Ophthalmologica. 1999;213:300–304.

50. Miller ML, Fraser PA, Jackson JM, et al. Inherited predisposition to iridocyclitis with juvenile rheumatoid arthritis: selectivity among HLA-DR5 haplotypes. Proc Natl Acad Sci U S A. 1984;81:3539–42.

51. Murray P. Serum autoantibodies and uveitis. Br J Ophthalmol. 1986;70:266–268.

52. Neuteboom GH, Hertzberger-ten Cate R, de Jong J, van den Brink HG, Feltkamp TE. Antibodies to a 15kD nuclear antigen in patients with juvenile chronic arthritis and uveitis. Invest Ophthalmol Vis Sci. 1992;33:1657–1660.

53. Ohno S, Char DH, Kimura SJ, O´Connor GR. HLA antigens and antinuclear antibody titres in juvenile chronic iridocyclitis. Br J Ophthalmol. 1977;61:59–61.

54. Ostensen M, Fredriksen K, Kass E, Rekvig OP. Identification of antihistone antibodies in subsets of juvenile chronic arthritis. Ann Rheum Dis. 1989;48:114–117.

55. Paroli MP, Abbouda A, Restivo L, Sapia A, Abicca I, Pivetti-Pezzi P. Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications. Ocul Immunol Inflamm. 2015;23:74–81.

56. Paroli MP, Speranza S, Marino M, Pirraglia MP, Pivetti-Pezzi P. Prognosis of juvenile rheumatoid arthritisassociated uveitis. Eur J Ophthalmol. 2003;13:616–621.

57. Reininga JK, Los LI, Wulffraat NM, Armbrust W. The evaluation of uveitis in juvenile idiopathic arthritis (JIA) patients: are current ophthalmologic screening guidelines adequate? Clin Exp Rheumatol. 2008;26:367–372.

58. Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J Aapos. 2008;12:539–545.

59. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56:647–657.

60. Schaller JG, Johnson GD, Holborow EJ, Ansell BM, Smiley WK. The association of antinuclear antibodies with the chronic iridocyclitis of juvenile rheumatoid arthritis (Still’s disease). Arthritis Rheum. 1974;17:409–416.

61. Sim KT, Venning HE, Barrett S, Gregson RM, Amoaku WM. Extended oligoarthritis and other risk factors for developing JIA-associated uveitis under ILAR classification and its implication for current screening guideline. Ocul Immunol Inflamm. 2006;14:353–357.

62. Southwood TR, Ryder CA. Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis? Br J Rheumatol. 1992;31:633–634.

63. Wakefield D, Herbort CP, Tugal-Tutkun I, Zierhut M. Controversies in ocular inflammation and immunology laser flare photometry. Ocul Immunol Inflamm. 2010;18: 334–340.

64. Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1990;33:1378–1383.

65. Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647–655.

66. Zannin ME, Buscain I, Vittadello F, et al. Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol. 2012;90:91–95.

67. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151:217–222.

68. Papadopoulou C, Kostik M, Böhm M, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163:879–884.

69. Saboo US, Metzinger JL, Radwan A, et al. Risk factors associated with the relapse of uveitis in patients with juvenile idiopathic arthritis: a preliminary report. J Aapos. 2013;17:460–464.

70. Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014;22:96–101.

71. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104:236–244.

72. Arocker-Mettinger E, Asenbauer T, Ulbrich S, Grabner G. Serum interleukin 2-receptor levels in uveitis. Curr Eye Res. 1990;9(Suppl 1):25–29.

73. Kalinina Ayuso V, de Boer JH, Byers HL, et al. Intraocular biomarker identification in uveitis associated with juvenile idiopathic arthritis. Invest Ophthalmol Vis Sci. 2013;54:3709–3720.

74. Heiligenhaus A, Foeldvari I, Edelsten C, et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res. 2012;64:1365–1372.

75. Walscheid K, Hennig M, Heinz C, et al. Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis-associated uveitis. Invest Ophthalmol Vis Sci. 2014;55:3447–3453.

76. Manzotti F, Orsoni JG, Zavota L, Cimino L, Zola E, Bonaguri C. Autoimmune uveitis in children: clinical correlation between antinuclear antibody positivity and ocular recurrences. Rheumatol Int. 2002;21:127–132.

77. Massa M, De Benedetti F, Pignatti P, Albani S, Monestier M, Martini A. Lack of temporal association of iridocyclitis with IgG reactivities to core histones and nucleosome subparticles in pauciarticular juvenile chronic arthritis. Br J Rheumatol. 1995;34:507–511.

78. Gregory AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186–192.

79. Yuce BY, Yilmaz SG, Kose S, Uretmen O. Outcome of pediatric uveitis at an university clinic. Turk J Ophthalmol. 2013;43:395–401.

80. Kotaniemi K, Sihto-Kauppi K, Salomaa P, Säilä H, Ristolainen L, Kauppi M. The frequency and outcome of uveitis in patients with newly diagnosed juvenile idiopathic arthritis in two 4-year cohorts from 1990-1993 and 2000-2003. Clin Exp Rheumatol. 2014;32:143–147.

81. Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–1441.

82. Olson NY, Lindsley CB, Godfrey WA. Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child. 1988;142:1289–1292.

83. Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology. 1987;94:1242–1248.

84. Sijssens KM, Rothova A, Van De Vijver DA, Stilma JS, De Boer JH. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;144:574–579.

85. Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology. 1993;100:809–817.

86. Yu EN, Meniconi ME, Tufail F, Baltatzis S, Foster CS. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm. 2005;13:353–360.

87. Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factoralpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34:1146–1150.

88. Shetty AK, Zganjar BE, Ellis GS, Ludwig IH, Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus. 1999;36:125–128.

89. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362–365.

90. Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17:743–748.

91. Goebel JC, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95:209–213.

92. Huang JL, Hung IJ, Hsieh KH. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pac J Allergy Immunol. 1997;15:71–75.

93. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416–1421.

94. Tappeiner C, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye. 2009;23:1192–1198.

95. Molina C, Modesto C, Martín-Begué N, Arnal C. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32:1673–1675.

96. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patiens with uveitis treated with infliximab. Ophthalmology. 2006;113:308–314.

97. Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572–575.

98. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324.

99. Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91:1341–1344.

100. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–550.

101. Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–1429.

102. García-De-Vicuńa C, Díaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:1–6.

103. Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritisassociated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601–1606.

104. Zholobova E, Galstian L, Nikolaeva MN, Loskutova OY. Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis. Pediatric Rheumatology. 2014;12(Suppl 1):O5.

105. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences i childhoodrefractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. 2011;63:612–618.

106. Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-& therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16.

107. Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45:1167–1172.

108. William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refraktory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2:231–233.

109. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252–257.

110. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33:461–468.

111. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860–864.

112. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritisassociated chronic anterior uveitis. Rheumatology. 2008;47:339–3344.

113. Trachana M, Pratsidou-Gertsi P, Pardalos G, Kozeis N, Badouraki M, Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. 2011; 40:101–107.

114. Díaz-Llopis M, Salom D, Garcia-de-Vicuńa C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.

115. Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor – α inhibitor. J Rheumatol. 2013;40:1394–1403.

116. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22:90–95.

117. Saeed MU, Raza SH, Goyal S, Cleary G, Newman WD, Chandna A. Etanercept in methotrexate-resistant JIA-related uveitis. Semin Ophthalmol. 2014;29:1–3.

118. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology. 2005;44:1008–1011.

119. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23.

120. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr. 2006;149:833–836.

121. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35:751–756.

122. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye. 2009;23:1868–1870.

123. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res. 2010;62:821-825.

124. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology. 2011;50:1390–1394.

125. Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Adán A. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121:2380–2386.

126. Angeles-Han ST, Griffin KW, Lehman TJ, et al. The importance of visual function in the quality of life of children with uveitis. J Aapos. 2010;14:163–168.

127. Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children ages 8-18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res. 2011;63:1254–1261.

128. Ezzahri M, Amine B, Rostom S, et al. The uveitis and its relationship with disease activity and quality of life in Moroccan children with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32:1387–1391.

129. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–2149.

130. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112–117.

131. Yu HH, Chen PC, Wang LC, et al. Juvenile idiopathic arthritis-associated uveitis: a nationwide population-based study in Taiwan. PLoS One. 2013;5:8.

132. Shen CC, Yeh KW, Ou LS, Yao TC, Chen LC, Huang JL. Clinical features of children with juvenile idiopathic arthritis using the ILAR classification criteria: a community-based cohort study in Taiwan. J Microbiol Immunol Infect. 2013;46:288–294.

133. Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm. 2013;21:180–191.

134. Sen, ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Best Pract Res Clin Rheumatol. 2017;31:517–534.

135. Ramanan AV, Guly C. Adalimumab for childhood onset uveitis. Ann Rheum Dis. 2018;77: 961–962.

136. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376:1637–1646.

137. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018;125(5):757–773.

138. Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J., 2018;16:46.

139. Wieringa WG, Ambrust W, Legger GE, Los LI. Efficacy of high-dose methotrexate in pediatric non-infectious uveitis. Ocul Immunol Inflamm. 2019;27(8):1305–1313.

140. LaMattina KC, Koreishi AF. What is new in pediatric uveitis? Curr Opin Ophtalmol. 2018;29: 412–418.

141. Quartier P, Baptiste A, Despert V On behalf of the ADJUVITE Study Group, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Annals of the Rheumatic Diseases. 2018;77:1003–1011.

142. Leinonen ST, Aalto K, Kotaniemi KM, Kivela TT. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017;35:1043–1046.

143. Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol. 2015;44:359–362.

144. Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37:549–553.

145. Skrabl-Baumgartner A, Seidel G, Langer-Wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019;104:246–250.

146. Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69:668–675.

147. Tappeiner C, Mesquida M, Adán A, et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2016;43:2183–2188.

148. Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361–1370.

149. Ramanan A, Dick AD, Jones AP, et al. A phase II trial protocol of tocilizumab in ati-TNF refraktory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2:1.

150. Ferrara M, Eggenschwiler L, Stephenson A, et al. The Challenge of Pediatric Uveitis: Tertiary Referral Center Experience in the United States. Ocul Immunol Inflamm. 2018;15:1–8.

151. Pleyer U, Algharably EA, Feist E, Kreutz R. Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opin Pharmacother. 2017;18: 1311–1323.

152. Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis, Seminars in Arthritis and Rheumatism. 2019;49:43–55.

153. Foeldvari I, Klotsche J, Simonini G, et al. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). Pediatr Rheumatol Online J. 2019;17(1):66.

Labels

Ophthalmology

VEGF: A KEY PLAYER NOT ONLY IN MACULAR DEGENERATION. A REVIEW

RESULTS OF 15 YEARS OF COLLABORATION BETWEEN THE DEPARTMENTS OF OPHTHALMOLOGY AND STOMATOLOGY IN ONCOLOGICAL SURGERY OF THE ORBIT: A DIAGNOSTIC AND THERAPEUTIC APPROACH

USAGE OF DIGITAL D CHART TEST AS A MODIFICATION OF AMSLER GRID IN OPHTHALMOLOGY AND OPTOMETRY

OCULAR COMPLICATIONS OF DIABETES MELLITUS IN PREGNANCY – CASE REPORT

Acute elevation of intraocular pressure in patient with hyperlipidemic myeloma

Article was published in

Czech and Slovak Ophthalmology

2020 Issue 4